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Inflammasomes form a crucial part of the innate immune system. These are multi-protein
oligomer platforms that are composed of intracellular sensors which are coupled with
caspase and interleukin activating systems. Nod-like receptor protein (NLRP) 3, and
6 and NLRC4 and AIM2 are the prominent members of the inflammasome family.
Inflammasome activation leads to pyroptosis, a process of programmed cell death distinct
from apoptosis through activation of Caspase and further downstream targets such as
IL-1β and IL-18 leading to activation of inflammatory cascade. Reactive oxygen species
(ROS) serves as important inflammasome activating signals. ROS activates inflammasome
through mitogen-activated protein kinases (MAPK) and extracellular signal-regulated
protein kinases 1 and 2 (ERK1/2). Dysregulation of inflammasome plays a significant role in
various pathological processes. Viral infections such as Dengue and Respiratory syncytial
virus activate inflammasomes. Crystal compounds in silicosis and gout also activate
ROS. In diabetes, inhibition of autophagy with resultant accumulation of dysfunctional
mitochondria leads to enhanced ROS production activating inflammasomes. Activation
of inflammasomes can be dampened by antioxidants such as SIRT-1. Inflammasome
and related cascade could serve as future therapeutic targets for various pathological
conditions.
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INTRODUCTION
Inflammation is a response of the body to tissue injury, and
plays an essential role in tissue repair when regulated. Chronic
inflammation is always pathological and a dysregulated inflam-
mation results in significant tissue damage. Inflammation is
induced by diverse stimuli, and is the outcome of a shift in
balance between various pro and anti- inflammatory cytokines.
Inflammasomes are newly discovered multi-protein oligomer
platforms that include Nod-like receptor protein (NLRP) 3 and
6, NLR family CARD domain-containing protein (NLRC) 4 and
Absent in Melanoma-2 (AIM2) protein. These play an important
role in initiating and sustaining inflammation (Wu et al., 2010).
The inflammasome is a component of the innate immune sys-
tem, and comprises an intracellular sensor such as NLRPs which is
coupled with procaspase-1 and the adaptor Apoptosis-associated
speck-like protein containing a carboxy-terminal CARD, i.e.,
ASC. Activation of inflammasome complex triggers the matura-
tion of caspase-1, resulting in the processing of interleukin 1β
(IL-1β) and IL-18. IL-1β is the most active cytokine in acute lung
injury patients (Ganter et al., 2008). The inflammasomes activate
inflammation to induce cell pyroptosis, a process of programmed
cell death different from apoptosis (Fink and Cookson, 2005),
and the exact nature of inflammasome depends on the activat-
ing agent. Pathogen-Associated Molecular Patterns (PAMPs) that
are predominantly of microbial origin and Damage-Associated
Molecular Patterns (DAMPs) that are released following micro-
bial or non-microbial tissue damage are two frequent stimulants
of inflammasome that induce maturation of pro-inflammatory
cytokines (Savage et al., 2012). NLRP3 inflammasome is prob-
ably the most widely studied and is activated by host-derived
molecules such as excess ATP, glucose, reactive oxygen species
(ROS), sphingosine, ceramides, oxidized LDL, uric acid, and crys-
tals of cholesterol (Duewell et al., 2010; Jiang et al., 2012; Luheshi
et al., 2012; Bandyopadhyay et al., 2013; Fukumoto et al., 2013).
Improper regulation of inflammasome production could
adversely affect the balance between pro- and anti-inflammatory
cytokines, leading to inflammation and pyroptosis. Though
NLRP3 inflammasome is widely studied, little is known about
the underlying molecular mechanisms that regulate its assem-
bly and activation. Recent studies show that generated by NLRP3
activators, ROS acts as second messengers whose signaling drives
inflammasome activation (Fukumoto et al., 2013; Heid et al.,
2013). There have been several excellent review articles that have
addressed inflammasomes, role of mitochondria in inflamma-
some activation, and inflammasomes in health and diseases. This
review will specifically address the role ROS plays in inflamma-
some activation and its implication in the pathology of human
diseases.
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NLR PROTEINS AND INFLAMMASOMES
Inflammasomes are classified into two families, viz., NLR and
PYHIN (pyrin and hematopoietic interferon-inducible nuclear
antigens domain-containing protein) (Fernandes-Alnemri et al.,
2009; Broz and Monack, 2011). The NLR family has more than
20 members currently known in humans that include nucleotide-
binding domain (NBD) and leucine-rich repeat (LRR) proteins
such as NLRP1, NLRP2, NLRP3, NLRP6, NLRC4, and NLRP12
(Correa et al., 2012; Allen et al., 2013; Chen, 2014). The LRR
domains of this family may be involved in auto-inhibition,
recognition of PAMPs, and protein-protein interactions. The
NBDs can bind ribonucleotides and possibly regulate homo-
or hetero-oligomerization, required for inflammasome assem-
bly. They also have a pyrin domain (PYD), a caspase activation
and recruitment domain (CARD), or both. The PYHIN family
members include AIM2 and Gamma-interferon-inducible pro-
tein (IFI16), and are characterized by a HIN200 ligand bind-
ing domain, in addition to the PYD that is involved in ligand
binding.
ROS IN NLRP3 INFLAMMASOME ACTIVATION
Recent studies suggest that ROS production is induced by many
NLRP3 inflammasome stimulators, and elevated ROS is essen-
tial for inflammasome activation; however, the cellular source of
ROS in mediating these responses remains unclear. ROS is pri-
marily a byproduct of mitochondrial oxidative phosphorylation.
During respiration, ∼1–2% of molecular oxygen (O2) is par-
tially reduced to superoxide and OH·, and the major sites of their
production in the mitochondrial respiratory chain are at com-
plex I and III. Complex I accepts electrons from NADH, which
move down an electrochemical gradient through ubiquinone to
complex III, then further down to cytochrome c and complex
IV where O2 is reduced to water. In addition to the mitochon-
drial electron transport chain, ROS is also generated in mam-
malian cells by the activity of enzymes such as NADPH oxidases
(NOXs), xanthine oxidase (XO), cyclooxygenase and lipoxyge-
nases (Habu et al., 1990; Lacy et al., 1998; Andrew and Mayer,
1999; Paravicini and Touyz, 2008). There is compelling evidence
that ROS production by NLRP3/NALP3 activators involves NOX
family of transmembrane proteins. These proteins generate ROS
by transporting electrons across biological membranes from a
cytosolic donor (NADPH) to an electron acceptor, O2, in the
extracellular or luminal space (Martinon, 2010; Nakahira et al.,
2011). While ROS generation is essential for cell signaling and
several important physiological responses, excessive accumula-
tion of ROS can lead to cellular damage and death. To mitigate
this oxidant stress, cells have several anti-oxidant defense mech-
anisms that include superoxide dismutase (SOD), glutathione
peroxidase (GPX), thioredoxin, catalase (CAT) and peroxiredox-
ins (Rahman et al., 2006; Johnson et al., 2010). ROS production
by polymorphonuclear leukocytes (PMN) and monocytes when
exposed to priming by NLRP3 activators regulates the activation
of redox-dependent transcriptional factors such as nuclear fac-
tor kappa-light-chain-enhancer of activated B cells (NF-kB) and
activator protein 1 (AP-1) via Mitogen-activated protein kinases
(MAP Kinases) and production of pro-inflammatory cytokines
(Kabe et al., 2005; Bauernfeind et al., 2009).
Animal studies have shown that activation of IL-1β and
caspase-1 is ROS-dependent (Dostert et al., 2008; Franchi et al.,
2009). In a positive feedback loop, IL-1β promotes intracellu-
lar accumulation of ROS by uncoupling superoxide dismutase
(SOD), glutathione peroxidase (GPX), and catalase (CAT). The
NLRP3 inflammasome is known to play a critical role in caspase-1
activation and the proteolytic processing of pro-IL-1β (Figure 1).
Activation of IL-1β and IL-18 inflammatory cytokines is inde-
pendently regulated by NLRP3 inflammasome. This has been
shown by using a “non-canonical” stimulus such as the secreted
Listeria monocytogenes (Lm) p60 protein. Primed murine den-
dritic cells (DCs) respond to p60 stimulation by producing ROS
and secreting IL-1β and IL-18 without any accompanying pyrop-
tosis. Inhibitors of ROS production inhibit secretion of IL-1β,
but not that of IL-18 (Schmidt and Lenz, 2012). Recent stud-
ies have demonstrated a role for CLOCK gene following acti-
vation of NALP3. A dose-dependent increase in CLOCK gene
expression is noted with increased oxygen concentrations. A sig-
nificant CLOCK gene down regulation occurs in Nalp3−/− mice
compared to wild-type controls, suggesting its role downstream
of NALP3 in mediating hyperoxia-induced lung inflammation
(Lagishetty et al., 2014). Exact mechanism(s) that regulates
NLRP3 inflammasome activation and its downstream activators
resulting in pyroptosis still remains unclear.
NLRX1, a recently identified member of the NLR family, plays
an active role in ROS production. In contrast to other NLR
family members which are located in the cytosol, NLRX1 is
specifically associated with the mitochondrial membrane and dif-
fers structurally from the other NLRs. NLRX1 shows structural
homology with the NOD-subfamily. Inflammatory signals like
TNF-α require NLRX1 for ROS production (Gavelli et al., 1990;
Álvarez and Muñoz-Fernández, 2013). Importance of NLRX1 in
caspase-1 activation and IL-1β signaling is yet to be characterized.
ROLE OF NOX PROTEINS IN NLRP3 INFLAMMASOME ACTIVATION
Among a host of inflammation-inducing agents, a common
convergence point that leads to activation of NLRP3 is yet to
be identified. ROS could act as a common event upstream
of the NLRP3 inflammasome machinery. NLRP3 is unique in
that its activation is quite sensitive to ROS inhibition (Heid
et al., 2013). NLRP3 inflammasome activation requires prim-
ing by pro-inflammatory signals whereas ROS inhibitors block
the priming of NLRP3. Moreover, pre-treatment of cells with
antioxidants inhibits NLRP3/NALP3 inflammasome activation,
suggesting a potential role for oxidative stress/redox signaling in
NLRP3/NALP3 activation (Bauernfeind et al., 2011; Hua et al.,
2013). The role of ROS in inflammasome activation has become
more evident as studies have shown that NLRP3-inflammasome
activators like silica, asbestos and ATP require ROS production
for their activity. In mammals, extracellular ATP binds to P2X7
receptors, induces rapid accumulation of ROS and activates the
NLRP3/NALP3 inflammasome (Riteau et al., 2012). The source
of ROS triggered by ATP seems to be NOX-derived, as the NOX
inhibitor, diphenyleneiodonium (DPI) inhibits ROS-dependent
ATP-mediated caspase-1 activation caused by ROS (Cruz et al.,
2007). Exposure to silica is known to result in ROS generation in
the bone marrow-derived macrophages from both wild type and
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FIGURE 1 | General schema describing the process of activation
of inflammasome: initiating factors activate production of
reactive oxygen species (ROS) which in turntriggers the
inflammasome mediated inflammatory cascade. Oligomerization of
components results in assembly of Inflammasome. This in turn
activates Il-1β and Il-18 through caspase-1. NLRP3 Inflammasome
promotes oxidative DNA damage. Inflammation and DNA damage
culminates in pyroptosis releasing contents from the damaged cell.
This in turn promotes a vicious cycle of further Inflammasome
mediated pathogenic process.
Nlrp3−/− mice, suggesting that ROS generation is upstream of
NLRP3 activation (Cassel et al., 2008). Similarly, uric acid crys-
tals, alum, and particulate metals are known to activate NLRP3
via ROS production mediated by mitochondrial or NOX pro-
tein activation. However, other NLRP3/NALP3 activators such
as nigericin (toxin) and UV light induce cellular redox imbal-
ance that is necessary for inflammasome formation (Martinon,
2010). Interestingly, ROS has also been implicated in inflam-
masome activation by hemozoin (malaria pathogen crystal), the
influenza virus and the yeast Candida albicans (Sakai et al., 1989;
Shio et al., 2009; Ichinohe et al., 2010). High concentrations of
calcium-binding Myeloid Related Proteins such as S100A8 and
S100A9 promote phagocytosis and have been noted in inflam-
matory conditions. They promote NOX activation by interaction
with p67phox and Rac-2 (Doussiere et al., 2002; Kerkhoff et al.,
2005). S100A8 and S100A9-mediated activation of NF-κB, the
NLR family, pyrin domain-containing 3 (NLRP3) protein, and
pro-IL-1β expression depend on the generation of ROS (Simard
et al., 2013).
Role of mitochondrial ROS in NLRP3 inflammasome activation
While NOX proteins seem to be the main source of ROS
in particle-induced phagocytosis and inflammasome activation,
mouse cells deficient in NOX2 show diminished ROS production
in response to various inflammasome activators, with a reduc-
tion in inflammasome activation (Abais et al., 2013). Additionally,
neutrophils derived from patients with chronic granulomatous
disease bearing mutation(s) in NOX2 display defective ROS pro-
duction, but inflammasome activation is unaffected (Meissner
et al., 2010) suggesting involvement of additional factors in regu-
lating inflammasome activation. Recent evidence suggests a role
for mitochondrial ROS in inflammasome activation indepen-
dent of NOX proteins. Using techniques to modify mitochon-
drial function and uncouple the respiratory chain, Zhou et al.,
has demonstrated redistribution of both NLRP3 and its adap-
tor ASC to the perinuclear space where they co-localize with
endoplasmic reticulum and mitochondria (Zhou et al., 2011).
Further, dysregulation of mitochondrial activity by inhibition
of the voltage-dependent anion channel suppresses ROS gen-
eration and inflammasome activation. Another salient feature
of this study is a role for mitophagy in inflammasome activa-
tion. Inhibition of mitophagy/autophagy with 3-methyladenine
results in accumulation of damaged mitochondria, increased
mitochondrial ROS, and activation of inflammasome, suggesting
that NLRP3 inflammasomemay sensemitochondrial damage and
dysfunction in inflammatory diseases (Zhou et al., 2011). IL-1β is
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recognized as a reliable marker for identifying ventilator-induced
lung inflammation. Cyclic stretch is known to activate NLRP3
inflammasomes and mechanical ventilation activates the NLRP3
inflammasomes in mouse alveolar macrophages, increasing the
production of IL-1β. IL-1β neutralization reduces mechani-
cal ventilation-induced inflammatory lung injury. Activation of
NLRP3 inflammasomes follows release of IL-1β in mouse alveolar
macrophages via caspase-1 and TLR4-dependent mechanisms. It
has been noted that mitochondrial generation of ROS is required
for stretch-induced NLRP3 inflammasome activation and IL-1β
release, whereas NOX2 is not essential (Kuipers et al., 2012; Wu
et al., 2013a).
Modulation of NLRP3 inflammasome by tripartite-motif protein 30
Tripartite-motif family of proteins or TRIM proteins is involved
in pathogen-recognition, and regulates transcriptional pathways
in host defense. TRIM30 negatively regulates NLRP3 inflam-
masome activation. Knockdown of TRIM30 enhances caspase-1
activation and increases production of IL-1β in bone marrow-
derived macrophages. TRIM30 knockdown increases ROS pro-
duction, which enhances NLRP3 inflammasome activation. On
the contrary, over-expression of TRIM30 attenuates ROS produc-
tion, and suppresses NLRP3 inflammasome activation; however,
the source of ROS has not been identified. In vivo experi-
ments in a crystal-induced NLRP3 inflammasome-dependent
peritonitis model using TRIM30 transgenic mice show signif-
icant reduction of monosodium urate-induced neutrophil flux
and IL-1β production as compared with that in their non-
transgenic littermates (Hu et al., 2010). These results indicate that
TRIM30 is a negative regulator of NLRP3mediated inflammatory
responses.
Potential role of micro RNAs in mediating ROS-induced
inflammasome activation
MicroRNAs serve as rheostats controlling NLRP3 activity.
Bandyopadhyay et al. has investigated the involvement of miR-
133a-1 in the activation of inflammasome (NLRP3) and IL-1β
production (Bandyopadhyay et al., 2013). Mitochondrial uncou-
pling protein 2 (UCP2) is elevated following exposure to hyper-
oxia and miR-133a-1 is known to target UCP2. Suppression of
UCP2 by siRNA enhances hydrogen peroxide (H2O2)-induced
inflammasome activity, but overexpression of UCP2 decreases
the inflammasome activation. This suggests that miR-133a-1
suppresses inflammasome by negatively regulating UCP2. The
miR-223, a myeloid specific microRNA is another critical reg-
ulator of NLRP3 inflammasome activity. miR-223 suppresses
NLRP3 expression through a conserved binding site within the 3′
untranslated region of NLRP3, leading to reduced NLRP3 inflam-
masome activity (Bauernfeind et al., 2012). The link between
ROS, microRNA and inflammasome activation is yet to be clearly
elucidated.
Mechanisms of ROS-induced NLRP3 activation
Several NLRP3 activators such as ATP, silica and asbestos trig-
ger ROS generation and its suppression using ROS scavengers
blocks NLRP3 activation. ROS is known to activate several mem-
bers of the tyrosine kinases, and G-protein-coupled receptors.
The downstream Raf kinase activates MEK1/2MAP kinase, which
in turn activates extracellular signal-regulated protein kinases
1 and 2 (ERK1/2) (Dhingra et al., 2007; Scholl et al., 2007).
ERK1/2 directs the cell toward a pro- or anti-apoptotic state
during inflammation. This is achieved by regulating expression
of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-18. A
decrease in ROS production is accompanied by decreased ERK1/2
activation along with decreased IL-1β production (Cruz et al.,
2007). ROS also activates inflammasome-activating signal trans-
duction pathways via PI3K. Recent studies have brought attention
to ROS-mediated activation of inflammasome via Thioredoxin
(TRX) and its endogenous inhibitor Thiredoxin-interactive pro-
tein (TXNIP) (Zhou et al., 2010). High levels of TXNIP inhibit
redox activity of cytoplasmic Thioredoxin-1 (TRX1) (Schulze
et al., 2004; Yoshihara et al., 2014) as well as mitochondrial
Thioredoxin-2 (TRX2) (Saxena et al., 2010). Oxidative stress
promotes translocation of TXNIP from nucleus to mitochon-
dria. TXNIP binds to TRX2, inhibiting its ability to keep ROS
level under check. In addition, TXNIP uncouples Apoptosis
signal-regulating kinase (ASK) 1-TRX2 binding. ASK1 that is
liberated gets phosphorylated, thereby activating Caspase-3 and
promoting apoptosis (Lane et al., 2013; Lu and Holmgren, 2014).
TXNIP released from oxidized TRX directly binds to leucine-
rich regions of NLRP3, leading to the formation of inflamma-
some (Figure 2). Further, ROS may directly activate caspase-1
and indirectly activate caspase-3 via ERK1/2. ERK1/2 activa-
tion by ROS is mediated by p53 as a result of the damage
to DNA by ROS. The exact interactions between ERK1/2 and
caspase-1 have not yet been delineated. During Libby Amphibole
(LA)-induced inflammation, components of the NALP3 inflam-
masome are transcriptionally activated. LA-induced activation of
inflammasome is known to contribute to fibrosis (Shannahan
et al., 2012). ROS is reported to be required for purinergic
P2X7 receptor (P2X7R)-mediated NALP3 inflammasome activa-
tion (Kishimoto et al., 1986; Solini et al., 2013). While the agonist
of P2X7, ATP is known to enhance hyperoxia-induced inflam-
masome activation, its antagonist, oxidized ATP suppresses the
same, as shown in human alveolar epithelial cells. It has been
noted that hyperoxia induces K+ efflux through the P2X7 recep-
tor, leading to inflammasome activation (Kolliputi et al., 2010).
Suppressor of cytokine signaling-1 (SOCS-1) functions as a nega-
tive regulator in ROS-induced apoptotic responses by promoting
ASK-1 degradation. SOCS-1 over-expressing mice are protected
from hyperoxia-induced inflammation, which is associated with
inactivation of inflammasome (Kolliputi and Waxman, 2009).
This demonstrates a critical role for SOCS-1 in inflammasome-
mediated inflammation. A model for NLRP3 activation called
APANAREI-axis has been suggested in macrophages. APANAREI
stands for “ATP-mediated P2X7-receptor Activation of NOX-
induced ROS production, which activates ERK1/2 and thereby
caspase-1 in the NLRP3-Inflammasome” (Kuiper, 2009). This
includes the P2X7- receptor, NOX, ROS, ERK1/2, NLRP3, and
caspase-1. In this model, ATP binds to P2X7, which up regu-
lates NOX-PI3Kinase, Ca2+ fluxes, activating MAP-Kinases and
ERK1/2. This involves caspase-1 activation in the inflamma-
some, resulting in cleaved IL-1β. NLRP3 activation by ROS
via ERK1/2 in the APANAREI-axis is based on observational
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FIGURE 2 | Role played by Thioredoxin Interactive Protein (TXNIP)
and Sirtuin in ROS induced inflammasome activation: Thioredoxin-1
(TRX1) and Thioredoxin-2 (TRX2) are part of key anti-oxidant
systems in cytoplasm and mitochondria respectively. Under stress
TXNIP is transferred from its usual location of nucleus to mitochondria
and cytosol. TXNIP in the nucleus binds to TRX2 uncoupling it from
ASK1. This results in ASK1 mediated activation of caspase-3 and
promotion of ROS production by virtue of removal of inhibitory action
of TRX2. Similarly TRX1 action is affected in the cytosol.Sirt1 is an
NAD+-dependent class III protein deacetylase which inhibits the
transactivation potential of NF-κb by deacetylation. This causes
suppression of NLRP3 transcription.
studies though the exact mechanisms of signaling downstream
of ERK1/2 to caspase-1 are still unclear. Along with mitochon-
drial apoptotic signaling, NF-κB serves as priming signal to
activate NLRP3 inflammasome, thereby increasing production
of IL-1β. ATP-induced mitochondrial dysfunction and apop-
tosis release oxidized mitochondrial DNA (mtDNA) into the
cytosol which binds and activates the NLRP3 inflammasome.
Macrophages lacking mtDNA have a dramatic decrease in IL-1β
production, but that does not prevent apoptosis. Bcl-2, which
is a known anti-apoptotic protein, inversely regulates mitochon-
drial dysfunction and NLRP3 inflammasome activation. Thus,
binding of cytosolic oxidized mtDNA to the NLRP3 inflam-
masome serves as one of the pathways leading to apoptosis
(Shimada et al., 2012).
Contradictory role of ROS in NLRP3 inflammasome activation
Although there is compelling evidence for the role of ROS
in inflammasome activation, some studies suggest a contra-
dictory role for ROS in inflammasome activation. Significantly
higher levels of ROS are found in Superoxide Dismutase-1
(SOD-1)-deficient macrophages, as they fail to detoxify reactive
superoxide species. These cells secrete relatively less amounts of
active IL-1β in response to inflammasome stimulants (Meissner
et al., 2010; van de Veerdonk et al., 2010). Similarly, SOD-1-
deficient mice are profoundly resistant to endotoxin-mediated
shock. The reason for this defective IL-1β cytokine response is
that elevated ROS levels in SOD-1–deficient cells decrease the
cellular redox potential, and reversibly oxidize and glutathiony-
late cellular components including caspase-1 (Meissner et al.,
2008). These studies suggest that ROS can have an inhibitory
effect on inflammasome activation. A recent study using phar-
macologic ROS inhibitors and small hairpin RNA (shRNA) to
knockdown p22phox in human monocytic cell lines has shown
that NOX activity and ROS stimulate rather than inhibit the
activation of caspase-1 (Dostert et al., 2008). The exact reasons
behind the observed contradictions over the role of NOX and
ROS in NLRP3 inflammasome activation are not clear. These
differences can be explained by species variations, differential
regulation of monocytes and macrophages, differences in spatio-
temporal localization of ROS, and the presence of functionally
redundant NOX proteins. Further, it is interesting to note that
while ROS is crucial for secretion of IL-1β via inflammasome
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activation, mice defective in ROS generation and patients with
chronic granulomatous diseases (CGD) have a pro-inflammatory
phenotype. Patients with CGDs have defective NOX2 activity and
hence cannot generate NADPH-dependent ROS. Interestingly, no
decrease in caspase-1 activation or secretion of IL-1β or IL-18 has
been observed in primary CGD monocytes. Compared to mono-
cytes from unaffected subjects, activation of CGD monocytes by
uric acid crystals induces a four-fold higher level of IL-1β secre-
tion in patients with CGD. This is accompanied by an increased
caspase-1 activation compared with control cells. Inhibition of
ROS activity in in vitro studies by DPI (diphenyleneiodonium
chloride) reveals an inhibition of IL-1β gene expression, result-
ing in a decrease in IL-1β secretion. Presence of an inflamma-
tory phenotype characterized by granulomas and inflammatory
bowel disease occurring in CGD patients may be explained iron-
ically by an absence of ROS aggravating alternate inflammatory
pathways.
Neutrophils are known to play a significant role in acute
inflammation by activating NOX and thereby promoting ROS
generation. Studies show that IL-1β processing in human neu-
trophils is dependent on caspase-1, elastase, and proteinase 3. It
has been shown that NOX2-deficient neutrophils not only acti-
vate caspase-1 but also express NALP3, indicating that ROS is
neither required for inflammasome activation nor for its prim-
ing, as has been reported for macrophages (Gabelloni et al.,
2013; Sokolovska et al., 2013). Recent advances have shown
that NOX need not be the primary source of ROS production
during inflammasome activation. Data show that the NLRP3
inflammasome/IL-1β secretion axis is a highly regulated inflam-
matory pathway which is susceptible to changes in mitochon-
drial and intracellular ROS, as well as overall mitochondrial
dysfunction. Experiments have been conducted in an inflam-
mation model of primary mouse peritoneal macrophages using
mitochondria-targeted drugs (Jabaut et al., 2013). The drugs
used to induce mitochondrial dysfunction are (1) antimycin A,
which blocks electron flow at complex III, (2) carbonyl cyanide-
p-trifluoromethoxyphenylhydrazone (FCCP), which uncouples
mitochondrial oxidative phosphorylation, (3) MnTBAP, a super-
oxide dismutase mimetic that targets the mitochondria, and
(4) DPI and Ebselen broad-spectrum antioxidants. It has been
noted that MnTBAP and ebselen block IL-1β secretion when
added before stimulation whereas DPI augments IL-1β secre-
tion. These effects are independent of the intracellular or mito-
chondrial ROS levels. It has also been found that FCCP sig-
nificantly sustains the association of the NLRP3 inflammasome
complex. Mitochondria-targeted drugs increase IL-1β secre-
tion independent of their impact on mitochondrial function
and ROS levels. This suggests that both mitochondrial ROS-
dependent and independent mechanisms play a role in the
NLRP3 inflammasome/IL-1β secretion axis in serum amyloid A
(SAA)-stimulated cells.
INFLAMMASOMES IN HUMAN PATHOLOGICAL CONDITIONS
Aberrations in inflammasomes have been implicated in the
pathogenesis of several human diseases such as microbial infec-
tions, metabolic syndromes, organ injury and mucosal immune
responses.
INFLAMMASOMES AND MICROBIAL/VIRAL INFECTION
A vital role for NLRP3 inflammasome has been implicated
in antibacterial, viral, fungal and parasitic immune responses;
however, a direct link between NLRP3 inflammasome activation
and the pathogen has been documented in only a few instances.
Dengue is currently the most rapidly spreading mosquito-borne
viral disease in the world, and the hemorrhagic form of the dis-
ease is a life threatening complication. Increased expression of
IL-1β in platelets and platelet-derived micro particles is observed
in patients with dengue or after platelet exposure to dengue
virus in vitro (Hottz et al., 2013). Dengue virus infection leads
to assembly of NLRP3 inflammasomes, activation of caspase-1
and caspase-1-dependent IL-1β secretion. Platelet-derived IL-1β
is mainly released as microparticles through mechanisms depen-
dent on mitochondrial ROS-triggered NLRP3 inflammasomes.
Inflammasome activation and platelet shedding of IL-1β-rich
microparticles correlates with increased vascular permeability
(Hottz et al., 2013). These findings show that platelets contribute
to increased vascular permeability in dengue virus infection by
inflammasome-dependent release of IL-1β. Caspase-1 activation
leading to up-regulation of pro-IL-1β, pro-IL-18, and NLRP3
is observed in dengue virus infected inflammatory macrophage
(GM-Mϕ). Blockade of CLEC5A/MDL-1, a C-type lectin criti-
cal for dengue hemorrhagic fever and Japanese encephalitis virus
infection, inhibits NLRP3 inflammasome activation and pyrotop-
sis in GM-Mϕ. Dengue virus activates NLRP3 inflammasome via
CLEC5A, and GM-Mϕ plays an important role in the pathogene-
sis of dengue infection (Wu et al., 2013b).
Human respiratory syncytial virus (RSV) causes life threaten-
ing respiratory diseases such as bronchiolitis and pneumonia in
newborn, children, elderly, and immune-compromised individu-
als. Mechanism of activation of inflammation involves activation
of TLR2/MyD88/NF-κB signaling, resulting in increased expres-
sion of pro-IL-1β and NLRP3 gene (Segovia et al., 2012). It is
crucial that intracellular ROS and K+ efflux due to stimula-
tion of ATP-sensitive ion channel promotes caspase-1-mediated
inflammasome activation following RSV infection. In addition to
NLRP3 inflammasome activation in viral infections, NLRP1 and
NLRC4 inflammasome activation is driven by type III and type IV
secretion systems (T3SS and T4SS) by Salmonella, Pseudomonas,
Legionella, and Yersinia bacteria (Elinav et al., 2011). Secretion
systems are transmembrane channels made up of large protein
complexes present in the cell envelope of many bacteria through
which proteins or protein–DNA complexes can be translocated
(Wallden et al., 2010). Interestingly, to avoid inducing inflam-
masome activation, many bacteria encode inhibitors such as
NS1 or Crm1, which directly modulate caspase-1 activity (Ray
et al., 1992; Stasakova et al., 2005). Similarly, ORF63 of Kaposi’s
sarcoma-associated herpes virus binds NLR sensors and blocks
formation of NLRP1 and NLRP3 inflammasomes (Gregory et al.,
2011). Study of the role of inflammasomes in tuberculosis shows
that the priming of primary murine microglial cells with con-
ditioned media from cultures of macrophages infected with
Mycobacterium tuberculosis (Mtb) results in activation of caspase-
1 and IL-1β secretion (Dorhoi et al., 2012). Mtb-induced IL-
1β maturation is found to depend on the generation of ROS
and inflammasome activation. Dexamethasone, which is used as
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an adjunctive therapy to reduce inflammation in patients with
tuberculous meningitis, significantly reduces the Mtb-induced
maturation of IL-1β through inhibition of mitochondrial ROS
generation (Lee et al., 2013). Future investigations need to address
how pathogens are sensed by inflammasomes and how inflam-
masomes interact with innate immune pathways to regulate
antimicrobial immune responses.
INFLAMMASOME ACTIVATION BY PARTICULATE AND CRYSTAL
COMPOUNDS
In addition to microbial infectious agents, many non-infectious
agents are known to induce inflammasome activation that is
linked to pathologies in humans and animals. Endocytosis
of inhaled silica and asbestos particles by residential lung
macrophages results in increased ROS generation, lysosome
destabilization and NLRP3 inflammasome activation, which
leads to silicosis and asbestosis, respectively (Cassel et al.,
2008; Hornung et al., 2008). Further, endogenous formation
of crystals from monosodium urate (MSU) and calcium phos-
phate may result in inflammasome activation in macrophages.
Accumulation of monosodium urate is characteristic of gout in
humans, but only recently aberrant NLRP3 inflammasome acti-
vation, NLRP3-dependent caspase-1 activation, and release of
IL-1β have been linked to its pathology. Impaired proteasomal
degradation by MSU crystals enhances p62 expression which
activates caspase-1 and IL-1β production. p62 is essential for
activation of inflammasomes responsible for acute inflammation
in gout (Amaral et al., 2012; Choe et al., 2014). Additionally,
studies conducted using monosodium urate (MSU) crystals in
murine dendritic cells (DC) from Nlrp3−/− mice suggest the role
of inflammasomes in the disease process. DCs from Nlrp3−/−
mice respond differently to MSU or other ROS-mobilizing stim-
uli (rotenone and γ-radiation) compared to DCs from WT
mice (Licandro et al., 2013). Furthermore, DNA fragmentation
is markedly reduced in DCs from Nlrp3−/− and Casp-1−/−
mice compared to those from WT mice. Another interesting
example of activation of NLRP3 inflammasome by exogenous
crystalline compound is by alum that is commonly used as an
adjuvant in human vaccines. In vitro exposure of macrophages
to alum leads to NLRP3-dependent activation of caspase-1
and NLRP3 inflammasome-deficient mice exhibit defects in
alum-induced adaptive immune responses (Franchi and Núñez,
2008). However, other studies suggest that alum-induced adap-
tive immune responses may be mediated by ASC activation
and recruitment independent of caspase-1 (McKee et al., 2009;
Ellebedy et al., 2011). Alternate NLRP3-independent mecha-
nism(s) for alum adjuvant effect has been proposed, which may
involve attachment of the adjuvant to the plasma membrane of
dendritic cells (Flach et al., 2011). These potential mechanisms of
adjuvant-mediated inflammation remain to be fully defined.
INFLAMMASOME ACTIVATION IN DIABETES
Inflammasomes may play a crucial role in pathobiology of dia-
betes. In macrophages, exogenous signals such as the saturated
fatty acids activate the NLRP3 inflammasome and promote
release of IL-1β. Fatty acid-activated AMP Kinase promotes
phosphorylation of Unc-51 like kinase (ULK1), which initiates
autophagy. The autophagy machinery controls mitochondrial
homeostasis by removing old or damaged mitochondria. Fatty
acids (e.g., palmitate) inhibit activation of AMP Kinase, lead-
ing to inhibition of autophagy. This results in accumulation of
dysfunctional mitochondria, accompanied by enhanced genera-
tion of ROS. Increased generation of mitochondrial ROS stimu-
lates activation of the NLRP3 inflammasome (Wen et al., 2011).
One of the drugs used for glycemic control glyburide, a sul-
fonyl urea that stimulates insulin secretion, acts as an inhibitor of
NLRP3 (Lamkanfi et al., 2009). Interestingly, therapeutic agents
blocking IL-1α signaling improve both glycemic control of diet-
induced obesity patients and pancreatic beta cell function in
animal models (Osborn et al., 2008; Owyang et al., 2010). This
suggests that the NLRP3 inflammasome is a promising thera-
peutic target in type 2 diabetes clinical trials. It has been shown
that pancreatic islet amyloid polypeptide in diabetics activates
NLRP3 inflammasome, as well as induces IL-1α secretion and
inflammation of the islets, leading to the development of pan-
creatitis and deranged glycemic control (Masters et al., 2010).
NLRP3 inflammasome activation is observed in chronic kidney
disease and diabetic nephropathy. Local IL-1α secretion partici-
pates in the onset of kidney inflammation (Vilaysane et al., 2010).
Atherosclerotic lesions containing abundant cholesterol crystals
have also been shown to be a potent activator of NLRP3 (Duewell
et al., 2010).
ALLERGIC CONTACT DERMATITIS AND INFLAMMASOME ACTIVATION
Exposure to an allergen causes hypersensitivity and elicits a T cell-
mediated inflammatory skin disease. Contact sensitizers activate
the oxidative stress pathway in keratinocytes and dendritic cells
(Corsini et al., 2013). ROS serves as essential second messenger
in activating the NLRP3/NALP3 inflammasome mediating cellu-
lar responses, resulting in immune cells activation (Martin et al.,
2011).
AGING, OXIDATIVE STRESS, AND INFLAMMASOME ACTIVATION
Recent studies have revealed that a low-level oxidative stress
is beneficial and can even extend the lifespan of organisms
(Cadenas and Davies, 2000). ROS constitutes important signaling
molecules required for autophagic degradation. Sirtuin1 (SIRT1),
effectively acts against oxidative stress and can stimulate the
expression of antioxidants via the FoxO pathway (Salminen et al.,
2013). SIRT1 inhibits NF-κB signaling which is a major inducer
of inflammatory responses via inflammasome pathway. ROS can
inhibit SIRT1 activity by initiating oxidative modifications on
its cysteine residues, and suppression of SIRT1 enhances the
NF-κB signaling resulting in inflammatory responses, including
inflammasome activation. Aging causes mitochondrial dysfunc-
tion with increased mitochondrial ROS, which could explain the
link between enhanced mitochondrial ROS and inflammasome
activation (Shimada et al., 2012).
HYPEROXIA, INFLAMMASOME ACTIVATION, AND ACUTE LUNG
INJURY
Oxygen therapy is an essential component in the management
of severe lung diseases and in respiratory distress syndrome
of preterm newborn. However, exposure to supra physiological
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concentration of oxygen could lead to hyperoxic acute lung
injury (HALI), and in vivo studies have shown that HALI is sup-
pressed in Nlrp3−/− mice compared with WT mice. Nlrp3−/−
mice exposed to hyperoxia develop less injury compared to
wild type mice, suggesting that HALI may be mediated through
NLRP3 inflammasome (Fukumoto et al., 2013). Hyperoxia-
induced recruitment of inflammatory cells and elevation of IL-
1β, TNFα, macrophage inflammatory protein-2, and monocyte
chemo attractant protein-1 are decreased in Nlrp3−/− mice.
NLRP3 deletion attenuates lung epithelial cell death, caspase-3
levels and NF-κB levels compared to WT controls. These stud-
ies suggest a role for NLRP3 inflammasome activation in the
development of hyperoxia-induced neonatal lung injury.
INFLAMMASOMES IN AUTOIMMUNE DISEASES
Systemic lupus erythematosus is characterized by an autoimmune
response against nuclear antigen of oneself, especially the dsDNA.
An increase in expression of the pro-inflammatory cytokine IL-
1β has been noted in the cutaneous lesion and Peripheral Blood
Mononuclear Cells (PBMCs) from lupus patients (Yang et al.,
2014). IL-1β promotes a Th17 cell response, which is increased in
lupus. Serum or purified IgG containing anti-dsDNA Abs along
with self dsDNA activates NLRP3 inflammasome. ROS, along
with K+ efflux, is involved in this activation. Inhibition of NLRP3,
caspase-1, ROS, and K+ efflux decreases IL-1β production. It has
also been noted that AIM2 expression is significantly increased in
apoptotic DNA-induced macrophages and closely correlates with
macrophage activation. Knockdown of AIM2 significantly blunts
apoptotic DNA-induced macrophage activation. These findings
provide new insights into the pathogenesis of lupus involving
inflammasomes (Zhang et al., 2013).
INFLAMMASOMES AND ATHEROSCLEROSIS
Accumulation of cholesterol in arterial plaques and IL-1β driven
progression of atherogenesis are hallmarks of atherosclerosis.
Recent microscopic evidence points to the presence of minute
cholesterol crystals in early high fat diet-induced atherosclerotic
lesions in LDL Receptor-KO mice, which coincides with the ini-
tial appearance of inflammatory cells in the lesions (Duewell et al.,
2010). Further, this study demonstrates that cholesterol crystals
activate NLRP3 inflammasome in resting or LPS-primed human
PBMCs suggesting potential common mechanisms involved
among the various crystals including monosodium urate. In vivo
intraperitoneal administration of cholesterol crystals induces
acute inflammation in WT mice, but not in mice deficient in
components of NLRP3 inflammasome, cathepsin B, cathepsin
L or IL-1 proteins. The most compelling evidence is obtained
from LDL Receptor-KO mice reconstituted with NLRP3-KO
bone marrow experiments wherein the aortic lesions are signif-
icantly smaller compared to mice reconstituted with wild-type
bone marrow (Duewell et al., 2010). However, the possibility
of oxidized-LDL-mediated activation of NLRP3 inflammasomes
in vivo remains to be verified. Similar to human PBMCs, human
macrophages also sense cholesterol crystals via NLRP3 inflam-
masomes (Rajamäki et al., 2010) suggesting NLRP3 as a ther-
apeutic target in atherosclerosis. However, a recent study using
the ApoE KO mice crossbred to NLRP3, ASC, or Caspase 1
KO mice shows no differences in atherogenesis or plaque stabil-
ity to high fat diet, indicating that NLRP3 inflammasome may
not play a role in atherogenesis in an ApoE-deficient mouse
model (Menu et al., 2011). Interestingly, Nrf2-deficient ApoE KO
mice are highly protected against high fat diet-induced athero-
genesis, suggesting that Nrf2 is essential in driving cholesterol
crystal-induced inflammation and exacerbation of atherosclero-
sis (Freigang et al., 2011). As ROS plays an important role in
inflammasome activation, and atherosclerosis has been linked
with mitochondrial dysfunction, it is reasonable to hypothesize
that damage induced by high-fat diet or aging contributes to
enhanced ROS production, which lowers the threshold required
to trigger NLRP3 inflammasome activation (Madamanchi and
Runge, 2007; Ordovas-Montanes and Ordovas, 2012). Further
studies are necessary to take the above observations that NLRP3
inflammasomes may play a role in atherogenesis and progression
of the disease from animal models to humans. The role played by
inflammasomes in various pathological conditions and potential
related therapeutic targets is summarized in Table 1.
CONCLUSION
Inflammasomes aremultiprotein oligomers of the innate immune
system that play a significant role in the pathogenesis of vari-
ous diseases that include lung injury, dengue hemorrhagic fever,
gout and diabetes mellitus. NLRP 3 and 6, NLRC4, and AIM2 are
the prominent members of the inflammasome family which also
includes precursor procaspase-1 and the adaptor ASC. Oxidant
damage from ROS plays a significant role as an initiating process.
Hyperoxia is also known to generate ROS which activates inflam-
masome sensor NLRP3. Activation of NLRP3 leads to activation
of CLOCK gene, caspase 1 and further downstream targets such
Table 1 | Types of inflammasome activated in various human diseases
and the potential therapeutic intervention.
Disease Inflammasome Potential related
activated therapeutic
intervention
Dengue NLRP3 Blockade of CLEC5A/MDL-1
Respiratory
syncytial virus
NLRP3 Blockade of TLR2/MyD88/NF-κB
signaling
Bacterial
infection
NLRP3, NLRP1,
NLRC4
Blockade of type III and type IV
secretion systems
Silicosis,
asbestosis,
gout
NLRP3 Blockade of p62 in gout
Diabetes NLRP3 Blockade of Unc-51 like kinase and
IL-1α signaling
Allergic
dermatitis
NLRP3, NALP3 –
Aging NLRP3 Sirtuin1
Hyperoxic lung
injury
NLRP 3 –
Autoimmune
diseases
NLRP 3 Blockade of AIM2
Atherosclerosis NLRP 3 Blockade of cathepsin B, cathepsin L
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as IL-1β and IL-18, leading to activation of inflammatory cascade,
pyroptosis and death of tissue. Various stimuli serve to activate
inflammasome through the common activator ROS, but TRIM-
30 and miR-133a-1 serve as suppressors of inflammasome activa-
tion. ROS activates inflammasome by MAP kinases and ERK1/2.
Antioxidants such as SIRT-1 limit activation of NLRP3 inflam-
masome and confer protection from injury. Further research
is required in understanding the mechanisms of activation of
inflammasome. Inhibiting the activation of inflammasome may
play a crucial therapeutic role for various pathological conditions
involving activation of inflammasome.
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